期刊文献+

Octavius 1600SRS三维剂量验证系统临床可行性测试 被引量:3

Feasibility of three-dimensional dose verification using Octavius 1600SRS
下载PDF
导出
摘要 目的:通过模体实验对PTW Octavius 1600SRS三维剂量验证系统进行临床应用前性能测试,评估其对立体定向放射治疗(SBRT)计划进行剂量验证的可行性。方法:选用PTWOctavius 1600SRS体模的CT图像,模拟勾画7个球形靶区,中心靶区(PTV_(0))直径大小为3 cm,其余各靶区直径大小分别为1.0 cm(2个)、1.5 cm(2个)和2.0 cm(2个),各靶区中心点距PTV_(0)中心点距离为3~6 cm。设置PTV_(0)的中心点为计划中心,在治疗计划系统中制定SBRT计划(Plan_(0)),处方剂量为8 Gy×3 F。实验分别对Plan_(0)引入临床常见偏差,包括叶片MLC位置偏差(1、2、3 mm)、计划中心点(ISO)位置偏差(1、2、3 mm)和机架位置偏差(0.5°、1.0°、2.0°),并生成相应的偏差计划。使用1600SRS验证系统分别对原计划和偏差计划进行测量,比较两者γ通过率和靶区覆盖率的差别,以评估系统对放疗剂量偏差的敏感性。另外,对6例临床SBRT计划进行治疗前剂量验证,并与EPID验证结果进行比较,以评估其临床计划验证性能。结果:1600SRS验证系统对MLC偏差检测非常敏感,当MLC出现1 mm偏差时,其γ通过率与各靶区覆盖率均出现显著下降,且随着MLC偏差变大,其下降越明显。当MLC出现3 mm偏差时,(3 mm/3%)和(2 mm/3%)的γ通过率分别从99.6%和98.0%下降至92.8%和81.7%,7个靶区体积的覆盖率(V_(98%))平均下降(58.8±6.8)%。1600SRS对机架旋转偏差和ISO平移误差检测亦敏感,在机架旋转出现2°偏差或ISO出现3 mm偏差时,其(2 mm/2%)的γ通过率分别从95.1%下降至89.5%或86.2%。另外,6例临床SBRT放疗计划的(2 mm/3%)γ通过率平均为(95.5±1.5)%。结论:Octavius 1600SRS能敏感地检测出SBRT计划中MLC到位偏差、机架旋转角度偏差与ISO偏差,能较好地应用于SBRT计划的治疗前剂量验证。 Objective To carry out performance test on PTW Octavius 1600SRS before clinical application through phantom experiment,and to evaluate the feasibility of dose verification for stereotactic body radiation therapy(SBRT)plan using PTW Octavius 1600SRS.Methods Seven spherical target areas,including a central target area(PTV_(0))with a diameter of 3.0 cm,2 target areas with a diameter of 1.0 cm,2 target areas with a diameter of 1.5 cm and 2 target areas with a diameter of 2.0 cm,were delineated in the CT image of the phantom in PTW Octavius 1600SRS.The distance from the center point of each target area to the center point of PTV_(0) was from 3 to 6 cm.With the central point of PTV_(0) as the planning center,the SBRT plan(Plan_(0))was designed in the treatment planning system,and its prescribed dose was 8 Gy×3 F.The experiment simulated and set the MLC position deviations(1,2,3 mm),the plan isocenter point(ISO)position deviations(1,2,3 mm)and the gantry rotation deviations(0.5°,1.0°,2.0°)for Plan_(0),and the corresponding deviation plans were generated.The 1600SRS verification system was used to measure the original plan and the deviation plans,and compare the difference of Gamma passing rate and target area coverage between the planned dose and the measured dose for evaluating the sensitivity of the system to radiotherapy dose deviation.In addition,pre-treatment dose verification using PTW Octavius 1600SRS was carried out in 6 cases of clinical SBRT plans,and then the results were compared with EPID verification results for evaluating its performance in clinical plan verification.Results The 1600SRS verification system was very sensitive to MLC position deviation.When a 1 mm deviation occurred in MLC,the gamma passing rate and the coverage rate of each target area were decreased significantly,and with the increase of MLC position deviation,the decrease was more obvious.When a 3 mm deviation occurred in MLC,the gamma passing rate decreased from 99.6%to 92.8%(3 mm/3%),and from 98.0%to 81.7%(2 mm/3%);and the coverage rates of 7 target areas(V_(98%))was decreased by(58.8±6.8)%on average.The 1600SRS was also sensitive to gantry rotation deviation and ISO translation error.When there was a 2°deviation in gantry rotation or a 3 mm deviation in ISO,the gamma passing rate(2 mm/2%)was decreased from 95.1%to 89.5%or 86.2%,respectively.The average gamma passing rate(2 mm/3%)in 6 cases of clinical SBRT plans was(95.5±1.5)%.Conclusion Octavius 1600SRS can detect MLC position deviation,gantry rotation deviation and ISO position deviation in SBRT plan sensitively,and can be used in pre-treatment dose verification for SBRT plan.
作者 周杨 刘懿梅 谭宇鸿 张俊 陈美宁 邓小武 彭应林 ZHOU Yang;LIU Yimei;TAN Yuhong;ZHANG Jun;CHEN Meining;DENG Xiaowu;PENG Yinglin(Tumor Radiotherapy Center,Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University,Zhuzhou 412000,China;Department of Radiation Oncology,Sun Yat-sen University Cancer Center/State Key Laboratory of Oncology in South China/Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China;Department of Medical Equipment,the First Dongguan Affiliated Hospital of Guangdong Medical University,Dongguan 523000,China)
出处 《中国医学物理学杂志》 CSCD 2022年第11期1321-1328,共8页 Chinese Journal of Medical Physics
基金 国家自然科学基金(12005316) 中华国际医学交流基金会肿瘤精准放疗星火计划(2019-N-11-20) 广州市科技计划项目(202206010154,202206010180)。
关键词 三维剂量验证系统 Octavius 1600SRS 立体定向放射治疗 剂量验证 γ通过率 three-dimensional dose verification system Octavius 1600SRS stereotactic body radiation therapy dose verification Gamma passing rate
  • 相关文献

参考文献5

二级参考文献40

  • 1戴建荣,胡逸民,张红志,关莹,张可,王闯.针对患者调强放射治疗计划的剂量学验证[J].中华放射肿瘤学杂志,2004,13(3):229-233. 被引量:65
  • 2黄晓延,黄劭敏,张黎,邓小武,钟宁山,陈立新.三维治疗计划系统的剂量学验证[J].中华放射肿瘤学杂志,2006,15(6):496-500. 被引量:26
  • 3Yin W, Chen B, Tian F, et al. The growth of radiation ontology in China's Mainland during the last 10 years[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3):795-798.
  • 4Levegrun S, Jackson A, Zelefsky MJ, et al. Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models [J]. Int J Radiat Oncol Biol Phys, 2000, 47(5):1245-1260.
  • 5Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis Of 938 patients irradiated in the prostate specific antigen era[J]. Cancer, 1997, 79(7):1370-1380.
  • 6Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized dose escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer[J]. J Clin Oncol, 2000, 18(23):3904-3911.
  • 7Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer[J]. Int J Radiat Oncol Biol Phys, 1998, 41(3):491-500.
  • 8Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer [J]. J Urol, 2001, 166(3):876-881.
  • 9Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy[J]. Cancer J Sci Am, 1999, 5(3):152-158.
  • 10Roach III M, Meehan S, Kroll S, et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate[J]. J Urol, 1996, 156(5):1719-1723.

共引文献52

同被引文献33

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部